Cyclarity Launches Human Trial to Cure Atherosclerosis

Cyclarity Therapeutics is working on a cost-effective small molecule drug aimed at eliminating arterial plaque, thus potentially addressing the globally leading cause of death: cardiovascular disease.

Its primary cyclodextrin drug candidate, UDP-003, focuses on 7-ketocholesterol, a type of oxidized cholesterol that increases in cells and tissues as people age. Atherosclerosis occurs when plaque accumulates in the arteries, primarily due to this oxidized cholesterol buildup.

This clinical trial will take place at CMAX, a leading clinical research center in Australia, in partnership with Monash University. As the clinical trial is set to start this year, we feel that this is the right moment to connect with Dr. Matthew O’Connor from Cyclarity to learn more about this important advancement. Dr. Matthew O’Connor formerly worked for the SENS Research Foundation, which merged with Lifespan.io last year to establish the Longevity Research Institute, where the initial concepts for Cyclarity originated. He now holds the position of CEO of Scientific Affairs at Cyclarity.

Full interview :

https://www.lifespan.io/news/cyclarity-launches-human-trial-to-cure-atherosclerosis/